<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468507</url>
  </required_header>
  <id_info>
    <org_study_id>067030</org_study_id>
    <nct_id>NCT00468507</nct_id>
  </id_info>
  <brief_title>The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application</brief_title>
  <official_title>The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing major surgery, trauma and burns are prone to develop an exacerbated
      inflammatory response, which is potentially lethal to the individual. Recently our group
      demonstrated that administration of high fat feeding prior to hemorrhagic shock attenuates
      severe inflammation, gut barrier loss and hepatic damage. High fat feeding releases
      cholecystokinin in the gut, which stimulates the autonomous nervous system and subsequently
      activates the efferent vagus nerve. The activated efferent fibers inhibit tissue macrophages
      via binding of acetylcholine to the alpha7-nicotinergic receptor.

      In this study the cholecystokinin release in healthy volunteers is monitored in response to
      low fat and high fat food products.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CCK-release</measure>
    <time_frame>two hours</time_frame>
  </primary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Trauma</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>nutritional intervention with Respifor and Diasip</intervention_name>
    <description>Four nutritional interventions on four separate days per test person</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females

          -  45 &gt; age &lt;55

        Exclusion Criteria:

          -  Gastrointestinal diseases

          -  Inflammatory conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Willem Greve, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2007</study_first_posted>
  <last_update_submitted>March 30, 2010</last_update_submitted>
  <last_update_submitted_qc>March 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>J.W.M. Greve, MD, PhD</name_title>
    <organization>Maastricht University Medical Center</organization>
  </responsible_party>
  <keyword>CCK release</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

